halofuginone has been researched along with Angiogenesis, Pathologic in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Assis, PA; Cândido, LA; Chahud, F; De Figueiredo-Pontes, LL; Falcão, RP; Garcia, AB; Leão, V; Lima, AS; Nagler, A; Panepucci, RA; Pintão, CT; Rego, EM; Saggioro, FP | 1 |
| Dafni, H; Gross, DJ; Nagler, A; Neeman, M; Pines, M; Reibstein, I; Slavin, S; Weiss, L | 1 |
| Fridman, E; Genina, O; Mor, Y; Nagler, A; Pines, M; Pinthus, JH; Sheffer, Y | 1 |
| Connolly, CM; Lawler, J; Pines, M; Yee, KO | 1 |
| Geffrotin, C; Gerritsen, MJ; Mamor-Cornelissen, I; Rijntjes, J; Ruiter, DJ; van Dijk, MC; van Kempen, LC; van Muijen, GN; Vincent-Naulleau, S | 1 |
| Ariel, I; de-Groot, N; Elkin, M; Hochberg, A; Miao, HQ; Nagler, A; Pines, M; Vlodavsky, I | 1 |
| Abramovitch, R; Dafni, H; Nagler, A; Neeman, M; Pines, M | 1 |
| Barak, V; Eshhar, Z; Gavish, Z; Nagler, A; Pines, M; Pinthus, JH; Ramon, J | 1 |
| Harris, AL; Streeter, EH | 1 |
1 review(s) available for halofuginone and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Angiogenesis in bladder cancer--prognostic marker and target for future therapy.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Cyclohexanes; DNA-Binding Proteins; Drug Combinations; Endothelial Growth Factors; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Nuclear Proteins; O-(Chloroacetylcarbamoyl)fumagillol; Piperidines; Quinazolines; Quinazolinones; Sesquiterpenes; Thymidine Phosphorylase; Transcription Factors; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
8 other study(ies) available for halofuginone and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model.
Topics: Animals; Disease Models, Animal; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolinones; Smad2 Protein; Tumor Cells, Cultured | 2015 |
Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.
Topics: Animals; Antineoplastic Agents; Cell Division; Collagen; Collagen Type I; Disease Progression; Electrophoresis, Polyacrylamide Gel; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pheochromocytoma; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rats; Temperature; Time Factors; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein | 2003 |
Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression.
Topics: Angiogenesis Inhibitors; Animals; Cell Line; Child, Preschool; Collagen; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Injections, Intraperitoneal; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones; Receptor, ErbB-2; Transplantation, Heterologous; Wilms Tumor; WT1 Proteins | 2005 |
Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism.
Topics: Animals; Antigens, Viral, Tumor; Antineoplastic Agents; Breast Neoplasms; Collagen Type I; Mice; Mice, Transgenic; Neovascularization, Pathologic; Piperidines; Polyomavirus; Quinazolines; Quinazolinones; Smad2 Protein; Smad3 Protein; Thrombospondin 1; Transforming Growth Factor beta; Tumor Burden | 2006 |
Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma.
Topics: Angiogenesis Inhibitors; Animals; Collagen Type I; Humans; Immunohistochemistry; In Situ Hybridization; Melanoma; Neoplasm Invasiveness; Neovascularization, Pathologic; Piperidines; Quinazolinones; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Swine; Swine, Miniature | 2008 |
Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone.
Topics: Animals; Antineoplastic Agents; Cell Division; Humans; Male; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Stromal Cells; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1999 |
Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis.
Topics: Animals; Antineoplastic Agents; Collagen; Dose-Response Relationship, Drug; In Situ Hybridization; Kinetics; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Time Factors; Tumor Cells, Cultured; Wound Healing | 1999 |
Growth inhibition of prostate cancer xenografts by halofuginone.
Topics: Adenocarcinoma; Administration, Oral; Androgens; Animals; Antineoplastic Agents; Apoptosis; Collagen Type I; Disease Progression; DNA, Neoplasm; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization; Injections, Intraperitoneal; Male; Mice; Mice, SCID; Necrosis; Neovascularization, Pathologic; Phenotype; Piperidines; Prostatic Neoplasms; Quinazolines; Quinazolinones | 2002 |